63rd American Society of Hematology (ASH)
December 11, 2021 ‐ December 14, 2021 in Atlanta
63rd American Society of Hematology (ASH) annual meeting will be held on December 11-14, 2021
Cellectis will present two posters. Details are below:
Poster Abstract Session:
Title: Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Abstract: #1746
Presenter: Jain Nitin, MD, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
Session Name: 704, cellular immunotherapies, Clinical Poster I
Date & Time & Location: December 11, 2021 5:30-7:30PM ET, Georgia World Congress Center, Hall B5
Poster Abstract Session:
Title: Pre-clinical development of a highly efficient TALEN®-based correction of β-globin gene in patient-derived hematopoietic stem and progenitor cells (HSPCs) to treat sickle cell disease
Abstract: #1856
Presenter: Julien Valton, PhD, Vice President Gene Therapy, Cellectis
Session Name: 801, Gene therapies Poster I
Session Date & Time & Location: Dec 11, 2021, 5:30-7:30PM ET, Georgia World Congress Center, Hall B5
ASH abstracts are now available on www.hematology.org